Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS ...
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results